News

Veru Inc. to Discuss Growth in Fiscal Q2 Results on May 8

Veru Inc. to Discuss Growth in Fiscal Q2 Results on May 8

Veru Inc. Financial Results Conference Call Announcement

Veru Inc. (NASDAQ: VERU), a prominent biopharmaceutical company specializing in innovative therapies for cardiometabolic and inflammatory diseases, is gearing up for an upcoming conference call. This enlightening event is set to take place on May 8 at 8:00 a.m. ET, where the company aims to share its fiscal results for the second quarter of 2025, along with insights into ongoing business developments.

How to Join the Conference Call

Participants interested in joining the call can conveniently do so via telephone. Domestic callers can dial 1-800-341-1602 while international attendees can reach the line at 1-412-902-6706. Simply ask to join the Veru Inc. call to be part of this informative session. In addition, an audio webcast will be available for online streaming, accessible through Veru's official site, under both the Home and Investors sections.

About Veru Inc. and Its Clinical Programs

Veru Inc. is at the forefront of developing next-generation treatment options aimed at addressing significant health concerns. The company’s current portfolio includes late-stage investigational drugs such as enobosarm and sabizabulin. Enobosarm is designed as a selective androgen receptor modulator (SARM) targeting body composition improvements, specifically aiding in fat loss while preserving lean body mass. This is especially vital in the context of older patients undergoing treatment with GLP-1 receptor agonists, which include medications like semaglutide (Wegovy).

Compelling Results from Recent Clinical Trials

In a recent Phase 2b clinical investigation named QUALITY, Veru announced promising results showcasing the effectiveness of enobosarm in promoting fat loss and preserving lean body mass among older patients who are overweight or obese. This multicenter, double-blind, placebo-controlled trial involved evaluating enobosarm in conjunction with semaglutide amongst participants, showing a distinct advantage in maintaining muscle mass while facilitating significant reductions in fat.

Key Findings from the QUALITY Study

The QUALITY trial confirmed that the combination of enobosarm and semaglutide yielded a remarkable 71% relative reduction in lean mass loss over 16 weeks. Moreover, those in the enobosarm 3mg group demonstrated a staggering 99% relative reduction in loss of lean mass, signifying the potential of this drug in enhancing body composition during weight management therapy.

Secondary outcomes of the trial further unveiled that participants on higher doses of enobosarm experienced a 46% greater loss of fat mass compared to the placebo group. This indicates enobosarm's capability to not just preserve muscle but also actively promote healthier fat distribution in the body, especially crucial for older adults battling obesity and related health challenges.

Ongoing Research and Future Directions

Veru is committed to pursuing additional research avenues beyond enobosarm. The company is also laying the groundwork for the clinical development of sabizabulin, a novel oral anti-inflammatory agent, which shows promise in treating inflammation linked to atherosclerotic cardiovascular disease. Atherosclerosis remains a leading cause of mortality globally, underscoring the urgency of Veru’s research efforts.

Potential Impact of Sabizabulin

With stable pharmacokinetics and a favorable safety profile, sabizabulin could offer a complementary solution to existing cholesterol-lowering therapies. Veru's approach hinges on the potential to simultaneously tackle both inflammation and cholesterol levels, thereby addressing a significant healthcare need. Preclinical studies have shown sabizabulin’s effectiveness in suppressing various inflammatory markers, bolstering its viability as a candidate for further clinical evaluation.

Conclusion

As Veru Inc. prepares to unveil its fiscal results on May 8, excitement mounts around the innovative drug developments underway within the company. The combination of enobosarm and semaglutide represents a promising advancement in the fight against obesity, while the potential of sabizabulin opens doors for tackling cardiovascular inflammation. Stakeholders and interested parties are encouraged to tune into the upcoming conference call for a comprehensive update on Veru’s advancements and future strategies.

Frequently Asked Questions

1. What is the purpose of Veru's conference call on May 8?

The conference call aims to discuss Veru's fiscal second-quarter financial results and provide a business update.

2. How can I participate in the Veru Inc. conference call?

Participants can join by dialing domestic 1-800-341-1602 or international 1-412-902-6706, or by accessing the audio webcast via Veru's website.

3. What are the main products being developed by Veru?

Veru is focused on developing enobosarm and sabizabulin, targeting obesity management and inflammation in cardiovascular diseases.

4. What were the results of the QUALITY clinical trial?

The trial indicated significant preservation of lean mass and enhanced fat loss among participants using enobosarm alongside semaglutide.

5. What future studies are planned for sabizabulin?

Veru aims to conduct a Phase 2 dose-finding trial for sabizabulin, focusing on its effectiveness in managing inflammation related to atherosclerotic cardiovascular disease.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 65

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 73

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 89

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 113

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Tackling the Industrialized Beast of Insurance Fraud

Updated Category News Views 62

Stepping Up the Fraud Fight This year's emerging fraud trends are taking the term 'organized crime' to new heights, and it's painting a bullseye on the insurance industry. The National Insurance Crime Bureau (NICB) just laid out how fraud isn't just a series of isolated scams anymore—it's an industrial-scale racket. As they spotlight during International Fraud Awareness...

Continue Reading
Ontario Airport Braces for Holiday Travel Surge

Updated Category News Views 92

Gearing Up for a Thanksgiving Travel Boom Think Thanksgiving brings only turkey to the table? Down in Ontario, California, it's all about jet fuel and passenger counts. The Ontario International Airport (ONT) is where the skies are buzzing, forecasting over 227,000 passengers trying to soak up the holiday vibes by air. Compare that to the numbers when the local folks...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 101

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 119

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading

Top 5 Most Recently Viewed Articles

Koin CU and North Star CCU Utilize Mahalo for Digital Banking

Updated Category News Views 151

Revolutionizing Member Experience with Mahalo’s Platform Koin Credit Union and North Star Community Credit Union are excited to announce their partnership with Mahalo Banking, leveraging the innovative Thoughtful Banking platform to enhance the digital banking experience for their members. This collaboration signifies a commitment by both credit unions to prioritize...

Continue Reading
Exploring the Short Interest Trends of Bloom Energy Corp

Updated Category News Views 409

Bloom Energy Corp: Understanding Recent Short Interest Trends Bloom Energy Corp (NYSE: BE) has recently seen its short interest as a percentage of float decrease by 3.47%. According to the latest data, about 39.43 million shares are sold short, equating to approximately 23.93% of the available shares for trading. This situation indicates that traders would require an...

Continue Reading
Hurricane Season 2025: Essential Travel Insurance Insights

Updated Category News Views 315

Hurricane Season 2025: What Travelers Need to Know As hurricane season approaches in 2025, there are increasing concerns about its potential severity. Experts anticipate this could be one of the most active seasons we have seen in years, with predictions suggesting an alarming number of storms. With the aviation sector facing ongoing challenges and emergency training...

Continue Reading
Allendale Social: Nominated for Best Dining Honors

Updated Category News Views 310

Allendale Social Recognized for Culinary Excellence Allendale Social has received nominations for two esteemed categories from 201 Magazine: Best Fine Dining and Best New Restaurant. This recognition highlights the restaurant's commitment to quality and the exceptional dining experience it has cultivated in a relaxed yet upscale environment. The voting process is crucial,...

Continue Reading
Insmed Induces Growth with New Employee Stock Grants

Updated Category News Views 167

Insmed's Strategic Inducement Grants Enhance Workforce Insmed Incorporated (Nasdaq: INSM), a leading global biopharmaceutical company, has recently made headlines by announcing a significant inducement grant aimed at bolstering its workforce. This initiative highlights Insmed's commitment to attracting top talent to support its mission of developing transformative...

Continue Reading